STOCK TITAN

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Syndax Pharmaceuticals (NASDAQ: SNDX) announced that CEO Michael A. Metzger will participate in a panel discussion focused on novel mechanisms in oncology at the Citi 2024 Global Healthcare Conference. The panel is scheduled for Thursday, December 5, 2024, at 11:00 a.m. ET. A live webcast will be available on the company's website investor section, with a replay option available for a time.

Loading...
Loading translation...
Argus Session date unavailable
+0.06% session move Open Argus
Details

News Market Reaction – SNDX

The recorded move for SNDX in the trading session of this news was +0.06%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WALTHAM, Mass., Nov. 27, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a panel discussion on novel mechanisms in oncology at the Citi 2024 Global Healthcare Conference on Thursday, December 5, 2024 at 11:00 a.m. ET.

A live webcast of the panel can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

Cision View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-citi-2024-global-healthcare-conference-302316980.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Syndax (SNDX) presenting at the Citi 2024 Global Healthcare Conference?

Syndax (SNDX) CEO Michael A. Metzger will participate in a panel discussion on December 5, 2024, at 11:00 a.m. ET.

What topic will Syndax (SNDX) discuss at the Citi 2024 Healthcare Conference?

Syndax will participate in a panel discussion focused on novel mechanisms in oncology.

How can investors access Syndax's (SNDX) panel discussion at the Citi Conference?

Investors can access the live webcast through the Investor section of Syndax's website at www.syndax.com, where a replay will also be available for a time.

Keep reading